Ileal sodium/bile acid cotransporter · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Ileal sodium/bile acid cotransporter shows approved-linked disease relevance led by intrahepatic cholestasis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q12908. Start with intrahepatic cholestasis, then reuse UniProt Q12908 as the stable protein anchor across project notes and exports.
Start with intrahepatic cholestasis, then reuse UniProt Q12908 as the stable protein anchor across project notes and exports.
Ileal sodium/bile acid cotransporter shows approved-linked disease relevance led by intrahepatic cholestasis. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with intrahepatic cholestasis because it currently carries approved-linked support. Linked drugs include LINERIXIBAT, ODEVIXIBAT, ODEVIXIBAT SESQUIHYDRATE, VOLIXIBAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyIleal sodium/bile acid cotransporter
Review this target as Ileal sodium/bile acid cotransporter, mapped to UniProt Q12908. Sequence length is 348 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Ileal sodium/bile acid cotransporter as ChEMBL target CHEMBL2778, mapped to UniProt Q12908. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Ileal sodium/bile acid cotransporter is the right protein anchor across sources, using UniProt Q12908 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why intrahepatic cholestasis is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Ileal sodium/bile acid cotransporter |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q12908 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Ileal sodium/bile acid cotransporter |
| UniProt Accession | Q12908 |
| Component Type | Protein |
| Sequence Length | 348 aa |
Ileal sodium/bile acid cotransporter
Review this target as Ileal sodium/bile acid cotransporter, mapped to UniProt Q12908. Sequence length is 348 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Ileal sodium/bile acid cotransporter shows approved-linked disease relevance led by intrahepatic cholestasis. 5 more disease programs remain visible in the same review block.
Start review with intrahepatic cholestasis because it currently carries approved-linked support. Linked drugs include LINERIXIBAT, ODEVIXIBAT, ODEVIXIBAT SESQUIHYDRATE, VOLIXIBAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL363392 | 9.55 | IC50 | 0.28 | Approved |
| CHEMBL370103 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL364676 | 9.3 | IC50 | 0.5 | Preclinical |
| CHEMBL194685 | 9.12 | IC50 | 0.75 | Preclinical |
| CHEMBL555246 | 9.12 | IC50 | 0.76 | Preclinical |
| CHEMBL372080 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL195012 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL3658914 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL332974 | 8.8 | IC50 | 1.6 | Preclinical |
| CHEMBL197508 | 8.7 | IC50 | 2.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 12 | 226 | 6.9 |
| assay format | 8 | 0 | — |
| single protein format | 6 | 77 | 6.8 |
| tissue-based format | 1 | 4 | 5.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| tissue-based format | 8 | 0 | — |
| cell-based format | 7 | 10 | 4.8 |
| assay format | 4 | 0 | — |